The antibody productivity of the human-human hybridoma cell line AE6, which produces the lung cancer specific human monoclonal antibody AE6F4, was enhanced fourfold upon stimulation with 1 µg/ml of vitamin A acetate for one day. The enhancement lasted for about two weeks, and could be repeated by another stimulation with vitamin A acetate. The enhancing effect of vitamin A acetate was influenced by the cell density. Enhancement was clearly observed when the cell density was under 10 6 cells/ml. However, when the cell density was over 10 7 cells/ml, enhancement was observed weakly or not at all. Although the enhancing effect of vitamin A acetate is not unique to AE6 cells, not all human-human hybridoma cell lines show increased productivity upon VA acetate stimulation. This study suggests that the response to vitamin A acetate may be related to the properties of a particular fusion partner which the hybridoma cell inherits. The efficacy of vitamin A acetate for production of human monoclonal antibodies using human-human hybridomas is discussed.
Introduction
Lung cancer is an increasingly serious problem in the industrialized world (Hespanhol et al., 1995; Nakayama et al., 1996) . The early detection of lung carcinomas is a most important key for the successful treatment of lung cancer (Chaiwun et al., 1996; Pierce et al., 1996) . The human monoclonal antibody (hMAb) AE6F4, which is produced by the humanhuman hybridoma AE6, has been shown to be potentially useful for the immunocytochemical detection of lung carcinomas in sputa (Shoji et al., 1994a, b) . Currently, using this hMAb AE6F4, an automated diagnosis system is being developed as alternative to chest X-ray diagnosis for the early detection of lung carcinomas. However, low productivity of humanhuman hybridomas remains a major obstacle for the implementation of such clinical trials. In previous papers, we reported the establishment of a recombinant hMAb AE6F4 hyperproducing BHK-21 cell line using the ras-oncogene activated production system (Yano et al., 1994; Inoue et al., 1996a) . Alternatively, we have also found that the productivities of AE6 cells could be significantly enhanced by stimulating the cells with vitamin A (VA) acetate. Aotsuka and colleagues reported that retinol and retinoic acid Figure 1 . Dose-response effect of VA acetate on varying cell densities of AE6 cells. AE6 cells were plated at initial density of 1 × 10 4 ( ), 1 × 10 5 ( ) or 1 × 10 6 ( ) cells/ml, and cultured in TES-ERDF medium supplemented with VA acetate at given concentrations for 5 days. On the 5th day, viable cell density and antibody concentration were examined. Figure 2 . Effects of a 5 day treatment of VA acetate on cell growth and antibody production. AE6 cells were cultured in TES-ERDF medium supplemented with ( ) or without ( ) 1 µg/ml of VA acetate for 5 days. Viable cell density and antibody concentration were determined every day.
enhanced antibody production in some human-human hybridoma cell lines (Aotsuka et al., 1991) . Retinoids such as VA acetate, retinol and retinoic acid have been shown to enhance the expression of many genes (Vu Dac et al., 1996; Minucci et al., 1997) , but there have been few reports describing how retinoids may boost the production of useful proteins including human monoclonal antibodies. In this paper, we suggest that the application of VA acetate may enhance the production of human monoclonal antibodies.
Materials and methods

Cells and cell culture
The human-human hybridoma cell line AE6, which produces the lung cancer specific hMAb AE6F4, and Figure 3 . Effects of VA acetate on antibody productivity of AE6 cells is time dependent. AE6 cells were treated with 1 µg/ml of VA acetate for various periods of time. Antibody productivities were compared between test and control cultures. Enhancement rate 1 refers to the productivity of the negative control culture.
the human-human hybridoma cell line BD9, which produces the lung cancer specific hMAb BD9D12, were both generated by fusing peripheral blood lymphocytes from a healthy adult with a T lymphoblastoid cell line A 4 H 12 derived from Molt4 cells using an in vitro immunization method (Kawahara et al., 1992; Shoji et al., 1994a) . The human-human hybridoma cell line HB4C5, which produces the lung cancer specific hMAb MAb-C5, was generated by fusing lymph node lymphocytes from a lung cancer patient with the B lymphoblastoid cell line NAT-30 derived from Namalwa cells (Murakami et al., 1985) . All cell lines were maintained in ERDF medium (Kyokuto Pharmaceutical Industrial. Co., Tokyo, Japan) supplemented with 5 µg/ml insulin (I), 20 µg/ml human transferrin (T), 20 µM ethanolamine (E) and 25 nM sodium selenite (S) (ITES-ERDF medium), at 37 • C in humidified 5% CO 2 /95% air. In the following experiments, the cells were cultured in TES-ERDF medium without insulin because insulin did not affect the cells during short time culture.
VA acetate
Vitamin A (VA) acetate in oil (1 500 000 IU/gram; Wako Pure Chemical Industries Co., Osaka, Japan) was dissolved in ethanol at a concentration of 1 mg/ml, and stored at -20 • C in small aliquots under light protection. For each experiment, stock aliquots were serially diluted with ethanol, and immediately added to the culture medium at final concentrations of 10 −3 to 10 µg/ml.
Measurement of antibody production and cell number
Antibody concentrations in the spent medium were measured by an enzyme-linked immunosorbent assay (ELISA) as described previously (Shoji et al., 1994a) , using anti-human immunoglobulin (Ig) antibodies (IgM #4102, IgG #4100; TAGO, Burlingame, CA, USA) as the first antibody, and anti-human Ig peroxide conjugate antibodies (IgM #2392, IgG #2390; TAGO, Burlingame, CA, USA) as the second antibody. Cell number was counted by using a cell counter, and viability was determined by the trypan blue dye exclusion method. All experiments were done in triplicate and the average value was used for analysis. Standard deviations were within 10%.
Dose-response effect of VA acetate on varying cell densities of AE6 cells
AE6 cells were plated in 35 mm plastic dishes at different initial densities of 1 × 10 4 , 1 × 10 5 and 1 × 10 6 cells/ml. Cells were cultured in TES-ERDF medium supplemented with VA acetate at various concentrations of 10 −3 to 10 µg/ml for 5 days. Control received an equal amount of ethanol instead of VA acetate. On 5th day, viable cell density and antibody concentration were examined. Time cources for growth and antibody production were also determined in TES-ERDF medium supplemented with or without 1 µg/ml of VA acetate.
Effects of VA acetate on antibody productivity of AE6 cells is time dependent
AE6 cells were treated with 1 µg/ml of VA acetate for a predetermined number of days, washed thoroughly, and replated in 35 mm plastic dishes at 1 × 10 5 cells/ml in TES-ERDF medium without VA acetate. On day 3, the viable cell density and antibody concentration were examined. A non treated culture was also done as control. Antibody productivities were compared between the test and control cultures.
Durability and reversibility of the enhancing effect of VA acetate
AE6 cells were plated in 60 mm plastic dishes at 1 × 10 6 cells/ml and treated with TES-ERDF me- Figure 4 . Durability and reversibility of effects of VA acetate. AE6 cells were treated with 1 µg/ml of VA acetate for one day as indicated by the arrow. After treatment, the cells were thoroughly washed and cultured in fresh TES-ERDF medium without VA acetate ( ). As control, a no treatment culture was also done in the same way ( ). During culture, the medium was changed daily, and antibody productivity was determined. Figure 5 . Effects of VA acetate on AE6 cells cultured in high density using a bioreactor system. AE6 cells were cultured in the hollow fiber bioreactor system Tecnomouse. The cells were precultured in TES-ERDF medium supplemented with 1 µg/ml of VA acetate for one day, and thereafter cultured in fresh TES-ERDF medium without VA acetate for another 10 days ( ). As a negative control, a non treated culture was performed in the same manner ( ). The spent medium in the culture cassette was recovered every other day, and the accumulated antibody concentration was detemined. Enhancement rate (dotted bar) 1 refers to the productivity of control culture wthout VA acetate. Aotsuka et al., 1991. dium supplemented with or without 1 µg/ml of VA acetate for one day. After treatment, the cells were thoroughly washed and cultured in fresh TES-ERDF medium without VA acetate for another 14 days. On the 14th day, 1 µg/ml of VA acetate was added to culture medium the same way as before. The medium was changed daily and the viable cell density and antibody concentration were determined every day.
High density culture of AE6 cells using a hollow fiber bioreactor system
High density cell culture was performed using the hollow fiber bioreactor system Tecnomouse (INTEGRA Bioscience Co., Germany) as described previously (Inoue et al., 1996b) . AE6 cells (7.5 × 10 7 cells/5 ml culture medium) were inoculated into the culture cassette of the system. The cells were precultured in TES-ERDF medium supplemented with 1 µg/ml of VA acetate for a day, and thereafter cultured in fresh TES-ERDF medium without VA acetate for another 10 days. Cells cultured at lower densities (7.5 × 10 6 cells/5 ml culture medium) in the presence of VA acetate were used as a positive control and without VA acetate as a negative control. The spent medium in culture cassette was recovered every other day, and the accumulated antibody concentration of each sample was measured by ELISA. Viable cell density in culture cassette could not be determined.
Results and discussion
Effects of VA acetate on cell growth and antibody production
A dose-response effect to VA acetate on different cell densities was examined using AE6 cells. On the 5th day, VA acetate was able to enhance the antibody production of all cell densities tested, and its enhancing effects appeared to be greater at lower cell densities (Figure 1 ). Optimum concentration of VA acetate was 1 µg/ml regardless of cell densities. At a concentration of 10 µg/ml, VA acetate was shown to be toxic to AE6 cells (Figure 1 ). Retinoids are known to act as potent surfactant at high concentrations.
After determination of optimum concentration, both cell growth and antibody production were monitored at this optimum concentration for 5 days. The growth of cells cultured in VA acetate containing medium was suppressed by about 30% compared to cells cultured in medium without VA acetate. Several retinoids were reported to inhibit proliferation in normal B cells and B cell-derived lines (Blomhoff et al., 1992; Pomponi et al., 1996) . In contrast, the antibody production of cells cultured in medium with VA acetate was about three times higher than cells cultured in medium without VA acetate (Figure 2 ). Growth rate suppression of hybridomas has previously been shown to enhance antibody productivity (Suzuki et al., 1990; Takahashi et al., 1994) .
Effects of VA acetate on antibody productivity is time dependent
The amount of time treatment with VA acetate required to enhance antibody productivity was examined. Treatment of cells with VA acetate for one day was enough to exhibit the enhancing effect, while longer treatment resulted in significant but lowered enhancing effect (Figure 3 ). Retinoids such as VA acetate are known to transcriptionally control many genes (Kontani et al., 1993; Desai et al., 1996) . Therefore, this decrease may be due to feedback repression of gene expression. At day one, the antibody productivity (3.2 µg/10 6 cells/3 days) increased to a maximum sevenfold as compared with control. A bioactive form of VA acetate, retinoic acid, also showed similar enhancing effects (data not shown). VA acetate was considered more favorable for antibody production than retinoic acid in terms of cost performance. The enhancing effect of VA acetate was maintained for at least two weeks and could be re-enhanced again by another stimulation with VA acetate, although the enhancing effect of the second stimulation could not be maintained for long a period of time (Figure 4) . It has been reported that retinoids act as a trigger for many cellular processes, including cellular differentiation (Rius et al., 1992) and embryogenesis (Eichele, 1989) . Therefore, these observations also suggest that VA acetate could act as a trigger for enhancing antibody production.
Enhancing effects of VA acetate on cells cultured in high density using a hollow fiber bioreactor system
The effect of VA acetate was examined on AE6 cells cultured in high density using the hollow fiber bioreacter system Tecnomouse. When the initial inoculating cell density is 1.5 × 10 7 cells/ml, the enhancing effect of VA acetate was observed weakly or not at all. However, significant enhancement was observed when cells were inoculated at a density of 1.5 × 10 6 cells/ml ( Figure 5 ). Even at the lower cell densities, the enhancement became weaker when the further a long culture was maintained, suggesting that this enhancement decrease may be due to the increased cell density. This tendency was also observed at the dish level (Figure 1) . Therefore, in high density culture, VA acetate may be effective only during the logarithmic growth phase when the cell density is low.
Enhancing effects of VA acetate on antibody productivity in other human-human hybridomas
In order to ensure whether VA acetate is applicable to other human-human hybridoma cell lines, BD9 and HB4C5 cell lines were cultured in TES-ERDF medium supplemented with or without 1 µg/ml of VA acetate for 5 days. The enhancing effect of VA acetate was observed in the BD9 cell line, but not in the HB4C5 cell line. As summerized in Table 1 , the antibody production enhancing effects of VA acetate was observed regardless of the Ig isotypes produced. Notably, enhancement was detected in the cell lines derived from the same fusion partner A 4 H 12 . These findings were similar to the data observed for retinoic acid (Aotsuka et al., 1991) . We also confirmed that enhancement can be achieved with retinoic acid in the AE6 and BD9 cell lines (data not shown). These observations suggested that the antibody production enhancing effects of retinoids might be related to the fusion partner rather than the B lymphocyte of hybridoma cell line. The fusion partner NAT-30, which is a IgM producing B lymphoblastoid cell line derived from Burkitt's lymphomas, has no sensitivity to VA acetate, which may be the reason why no enhancement is seen in the HB4C5 cell line. However, in some B lymphoblastoid cell lines such as the Epstein-Barr virus transformed B cell line, antibody production is enhanced by retinoids (Wang et al., 1993; Ballow et al., 1996) . These facts suggest that the response to retinoids is different depending upon the properties of B lymphoblastoid cell line. On the other hand, the fusion partner A 4 H 12 does not produce antibody because it is a T lymphoblastoid cell line. However, retinoids are reported to be important cofactors in T cell activation (Garbe et al., 1992) , indicating that this may be the reason why A 4 H 12 derived hybridomas respond to VA acetate. These findings suggest that VA acetate may be a useful tool for enhancing the production of antibodies in human-human hybridomas if the selection of fusion partners is done carefully.
Conclusions
We report here that VA acetate is effective for enhancing the production of lung cancer specific hMAbs in human-human hybridomas under certain conditions. Cell density, VA acetate concentration, and the time of treatment are important to obtain effective enhancement of antibody production. When the cells were cultured in high density, VA acetate was effective during the growth phase when densities were lower than 10 6 cells/ml. Therefore, VA acetate should be effective for enhancing antibody productivity on the medium production scale. The enhancing effects of VA acetate on the antibody productivity of human-human hybridomas seemed to be associated with the properties inherited from the fusion partner. However, to demonstrate this hypothesis, more detailed research on the properties of the fusion partners and the enhancing mechanisms itself is needed.
